pSTAT5 is detected in human breast early lesions, especially in women who have had a pregnancy; therefore, prophylactic therapy targeting Jak2-STAT5 signaling may lower breast cancer risk in high risk women. This evidence concerns the gene JAK2 and breast cancer.